| ecopipam (PSYRX 101) / Paragon Biosci |
NCT01065558: Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease |
|
|
| Completed | 1 | 5 | US | Ecopipam, PSYRX101, SCH 39166 | Psyadon Pharma | Lesch-Nyhan Disease | 01/11 | 06/11 | | |
NCT01408394: Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam |
|
|
| Completed | 1 | 16 | US | Ecopipam immediate release form, SCH 39166, PSYRX101, 90 mg controlled release form, 180 mg controlled release form | Emalex Biosciences Inc., Psyadon Pharma | Healthy | 02/12 | 05/12 | | |
| Terminated | 1 | 30 | US | ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail | Emalex Biosciences Inc., Syneos Health, Nuventra | Drug-Interactions | 04/21 | 05/21 | | |
EBS-101-HV-102, NCT04902105: Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite |
|
|
| Completed | 1 | 38 | US | ecopipam HCL, Mefenamic acid, Divalproex Sodium ER | Emalex Biosciences Inc., Syneos Health, Nuventra | Drug Interaction | 07/21 | 07/21 | | |
| Completed | 1 | 8 | Europe | [14C]-Ecopipam | Emalex Biosciences Inc., Covance | Healthy Volunteer | 09/21 | 09/21 | | |
EBS-101-HV-104, NCT05334108: Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport |
|
|
| Completed | 1 | 56 | US | Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail | Emalex Biosciences Inc., ICON Early Phase Services, Nuventra | Drug Interaction | 08/22 | 08/22 | | |
| Completed | 1 | 29 | US | Ecopipam Hydrochloride, Moxifloxacin, Placebo | Emalex Biosciences Inc., PPD, Clario | QT/QTc | 05/23 | 05/23 | | |
| Recruiting | 1 | 40 | Canada | Itraconazole, rifampicin, Ecopipam | Emalex Biosciences Inc., Syneos Health, Cambridge Cognition Ltd | Drug Interaction | 05/24 | 05/24 | | |
